Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous-infusion 5-fluorouracil in metastatic breast cancer.
Twenty-six patients with metastatic breast cancer were offered a phase II combination of recombinant alpha-interferon and continuous-infusion 5-fluorouracil (5-FU). 5-FU was administered at 750 mg/m2 daily for 5 days as a continuous infusion and recombinant interferon at 5 million U/m2 subcutaneously days 1,3, and 5 of each course. The courses were repeated every 14 days. Despite moderate nonmyelosuppressive toxicity, only two (8%) partial remissions were observed. In this schedule, the addition of recombinant alpha-interferon to conventional continuous-infusion 5-FU resulted in a response rate of 8%.
Walters
R S
RS
Department of Breast and Gynecologic Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030-4009, USA.
Theriault
R L
RL
Booser
D J
DJ
Esparza
L
L
Hortobagyi
G N
GN
D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007167:Immunotherapy; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D007370:Interferon Type I / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D011994:Recombinant Proteins
D007370:Interferon Type I; D011994:Recombinant Proteins; D005472:Fluorouracil